Discordant susceptibility of inbred C57BL/6 versus outbred CD1 mice to experimental fungal sepsis

Cell Microbiol. 2019 May;21(5):e12995. doi: 10.1111/cmi.12995. Epub 2019 Jan 9.

Abstract

Individual susceptibility differences to fungal infection following invasive and/or immunosuppressive medical interventions are an important clinical issue. In order to explore immune response-related factors that may be linked to fungal infection susceptibility, we have compared the response of inbred C57BL/6J and outbred CD1 mouse strains to different experimental models of fungal sepsis. The challenge of animals with the zymosan-induced generalised inflammation model revealed poorer survival rates in C57BL/6J, consistent with lower Th1 cytokine interferon (IFN)-γ serum levels, compared with CD1 mice. Likewise, ex vivo exposure of C57BL/6J splenocytes to zymosan but also bacterial lipopolisaccharide or lipoteichoic acid, resulted in lower IFN-γ secretion compared with CD1 mice. C57BL/6J susceptibility could be reverted by rescue infusion of relative low IFN-γ doses (0.2 μg/kg) either alone or in combination with the ß-glucan-binding CD5 protein (0.7 mg/kg) leading to improved post zymosan-induced generalised inflammation survival. Similarly, low survival rates to systemic Candida albicans infection (2.86 × 104 CFU/gr) were ameliorated by low-dose IFN-γ infusion in C57BL/6J but not CD1 mice. Our results highlight the importance of strain choice in experimental fungal infection models and provide a susceptibility rationale for more specific antifungal immunotherapy designs.

Keywords: C57BL/6J mice; CD1 mice; Candida albicans; IFN-γ; fungal sepsis; zymosan.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Outbred Strains
  • Bacterial Outer Membrane Proteins / immunology
  • CD5 Antigens / administration & dosage
  • Candida albicans / immunology
  • Candida albicans / pathogenicity
  • Candidiasis / drug therapy
  • Candidiasis / immunology*
  • Cytokines / blood
  • Disease Models, Animal
  • Disease Susceptibility / immunology*
  • Disease Susceptibility / microbiology
  • Interferon-gamma / administration & dosage
  • Interferon-gamma / blood
  • Interferon-gamma / therapeutic use*
  • Lipopolysaccharides / toxicity
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mycoses / drug therapy
  • Mycoses / immunology*
  • Sepsis / drug therapy
  • Sepsis / immunology*
  • Sepsis / microbiology
  • Sepsis / mortality
  • Species Specificity
  • Spleen / cytology
  • Spleen / drug effects
  • Spleen / metabolism
  • Teichoic Acids / toxicity
  • Zymosan / toxicity

Substances

  • Bacterial Outer Membrane Proteins
  • CD5 Antigens
  • Cd5 protein, mouse
  • Cytokines
  • Lipopolysaccharides
  • TLR protein, bacteria
  • Teichoic Acids
  • lipoteichoic acid
  • Interferon-gamma
  • Zymosan